Published in Cancer Epidemiol Biomarkers Prev on May 01, 2001
An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One (2009) 3.33
Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol (2004) 1.88
Bead-based ELISA for validation of ovarian cancer early detection markers. Clin Cancer Res (2006) 1.52
Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.52
Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single-threshold rule. J Clin Oncol (2012) 1.48
Effects of blood collection conditions on ovarian cancer serum markers. PLoS One (2007) 1.27
Cancer screening: a mathematical model relating secreted blood biomarker levels to tumor sizes. PLoS Med (2008) 1.21
Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiol Biomarkers Prev (2009) 1.16
The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecol Oncol (2008) 1.14
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age. Am J Obstet Gynecol (2011) 1.12
Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. Cancer Prev Res (Phila) (2011) 1.10
Aberrant glycosylation as biomarker for cancer: focus on CD43. Biomed Res Int (2014) 0.97
Analysis of second-harmonic-generation microscopy in a mouse model of ovarian carcinoma. J Biomed Opt (2012) 0.94
Abnormal CA-125 levels in menopausal women without ovarian cancer. Gynecol Oncol (2014) 0.91
Serum folate receptor alpha, mesothelin and megakaryocyte potentiating factor in ovarian cancer: association to disease stage and grade and comparison to CA125 and HE4. J Ovarian Res (2013) 0.91
Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol (2010) 0.89
Epidemiological and genetic factors associated with ovarian cancer. Cancer Nurs (2009) 0.88
HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection. Oncol Lett (2012) 0.81
Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women. Cancer Epidemiol Biomarkers Prev (2014) 0.78
Glycomic Approaches for the Discovery of Targets in Gastrointestinal Cancer. Front Oncol (2016) 0.77
Utility of preoperative neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to distinguish malignant from benign ovarian masses. J Turk Ger Gynecol Assoc (2016) 0.75
A novel splicing mutation in the SLC9A3R1 gene in tumors from ovarian cancer patients. Oncol Lett (2015) 0.75
Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. J Ovarian Res (2017) 0.75
Circulating biomarkers in epithelial ovarian cancer diagnosis: from present to future perspective. Ann Transl Med (2017) 0.75
Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes Control (2017) 0.75
Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA (1998) 6.34
Screening for ovarian cancer: a pilot randomised controlled trial. Lancet (1999) 5.81
Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 5.39
An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med (1996) 3.86
New tumor markers: CA125 and beyond. Int J Gynecol Cancer (2005) 2.92
Race, ethnicity, and the health care system: public perceptions and experiences. Med Care Res Rev (2000) 2.86
Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer. Gynecol Oncol (2002) 2.41
Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound Obstet Gynecol (2013) 2.11
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. Gynecol Oncol (2000) 2.04
The clinical course of osteoporosis in anorexia nervosa. A longitudinal study of cortical bone mass. JAMA (1991) 1.93
p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet (1998) 1.79
Elevation of multiple serum markers in patients with stage I ovarian cancer. J Natl Cancer Inst (1993) 1.71
Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin. Ann Intern Med (2001) 1.69
PTEN methylation is associated with advanced stage and microsatellite instability in endometrial carcinoma. Int J Cancer (2001) 1.63
Missed opportunities: teenagers and emergency contraception. Arch Pediatr Adolesc Med (1998) 1.62
Genetic intra-tumour heterogeneity in epithelial ovarian cancer and its implications for molecular diagnosis of tumours. J Pathol (2007) 1.61
Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst (1993) 1.60
Aggressive early medical management by a specialist in physical medicine and rehabilitation: effect on lost time due to injuries in hospital employees. J Occup Med (1990) 1.55
Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med (2000) 1.55
Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. Br J Cancer (2009) 1.54
Screening for ovarian cancer. Ann Intern Med (1994) 1.53
Prevalence of antineutrophil cytoplasmic antibodies in a large inception cohort of patients with connective tissue disease. Ann Intern Med (1997) 1.40
Validity of self-reported mammography in low-income African-American women. Am J Prev Med (1998) 1.39
Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation (1999) 1.29
Combinations of multiple serum markers are superior to individual assays for discriminating malignant from benign pelvic masses. Gynecol Oncol (1995) 1.27
Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG (2011) 1.23
Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Pathol (2002) 1.21
Molecular quantification and mapping of lymph-node micrometastases in cervical cancer. Lancet (2001) 1.21
Influences on multidisciplinary team decision-making. Int J Gynecol Cancer (2007) 1.19
Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Br J Cancer (2009) 1.19
Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. Br J Cancer (2010) 1.18
Predicting mammography and breast self-examination in African American women. Cancer Nurs (1997) 1.17
Do benefits and barriers differ by stage of adoption for colorectal cancer screening? Health Educ Res (2004) 1.17
Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG (2007) 1.15
Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. Br J Cancer (1999) 1.13
Colorectal cancer screening beliefs. Focus groups with first-degree relatives. Cancer Pract (2000) 1.13
The role of CA 125 in screening for ovarian cancer. Int J Biol Markers (1999) 1.12
Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Ultrasound Obstet Gynecol (2012) 1.11
A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer. Br J Cancer (1999) 1.10
Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. Br J Cancer (2009) 1.08
Ascites and a raised serum Ca 125--confusing combination. J R Soc Med (2001) 1.08
Are we making progress with emergency contraception? Recent findings on American adults and health professionals. J Am Med Womens Assoc (1998) 1.08
A model for co-expression pattern analysis of genes implicated in angiogenesis and tumour cell invasion in cervical cancer. Br J Cancer (2002) 1.08
Changing blood use in the AIDS era: the case of elective hip surgery. Transfusion (1994) 1.07
Conotoxin GI: disulfide bridges, synthesis, and preparation of iodinated derivatives. Biochemistry (1984) 1.07
Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG (2000) 1.03
Recent developments in ovarian cancer screening. Curr Opin Obstet Gynecol (2000) 1.02
The role of magnetic resonance imaging and ultrasound in patients with adnexal masses. Clin Radiol (2005) 1.02
Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif (2009) 1.02
Analysis of c-erbB-2 expression in breast carcinomas with clinical follow-up. Cancer Res (1989) 1.02
Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. Radiology (1999) 1.00
Simulation modeling of outcomes and cost effectiveness. Hematol Oncol Clin North Am (2000) 1.00
Trans-10, cis-12, but not cis-9, trans-11, conjugated linoleic acid attenuates lipogenesis in primary cultures of stromal vascular cells from human adipose tissue. J Nutr (2001) 1.00
Ovarian cancer screening in the general population. Curr Opin Obstet Gynecol (2001) 0.99
Isolation and structure of a peptide toxin from the marine snail Conus magus. Arch Biochem Biophys (1982) 0.98
Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21,715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. Br J Cancer (2010) 0.98
Quercetin attenuates inflammation in human macrophages and adipocytes exposed to macrophage-conditioned media. Int J Obes (Lond) (2011) 0.98
Methylation of hMLH1 in a population-based series of endometrial carcinomas. Clin Cancer Res (2000) 0.97
Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gynecol Cancer (2007) 0.97
Early detection of cancer in the general population: a blinded case-control study of p53 autoantibodies in colorectal cancer. Br J Cancer (2012) 0.96
Benzodiazepines: are we overprescribing? Can Fam Physician (1987) 0.96
Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. BJOG (2006) 0.96
Frequency and prognostic impact of microsatellite instability in a large population-based study of endometrial carcinomas. Cancer Res (2000) 0.95
Surgical morbidity associated with radical trachelectomy and radical hysterectomy. Gynecol Oncol (2005) 0.95
Risk of epithelial ovarian cancer in asymptomatic women with ultrasound-detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound Obstet Gynecol (2012) 0.94
Screening for ovarian cancer. Ann Acad Med Singapore (1998) 0.93
Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. Br J Cancer (2013) 0.92
Detection of tumour lymphovascular space invasion using dual cytokeratin and CD31 immunohistochemistry. J Clin Pathol (2003) 0.90
Can MRI rule out bladder and rectal invasion in cervical cancer to help select patients for limited EUA? Gynecol Oncol (2005) 0.90
Design issues for conducting cost-effectiveness analyses alongside clinical trials. Annu Rev Public Health (2001) 0.89
Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary Pneumocystis carinii prophylaxis. Control Clin Trials (1999) 0.89
The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. Br J Urol (1998) 0.89
Survival analysis in familial ovarian cancer, a case control study. Eur J Obstet Gynecol Reprod Biol (2001) 0.89
Tailoring interventions for health behavior change in breast cancer screening. Cancer Pract (1997) 0.89
Experience of symptoms indicative of gynaecological cancers in UK women. Br J Cancer (2013) 0.89
Ovarian cancer screening in the general population: current status. Int J Gynecol Cancer (2001) 0.88
Conjugated linoleic acid suppresses triglyceride accumulation and induces apoptosis in 3T3-L1 preadipocytes. Lipids (2000) 0.88
The impact of age and race on mammography practices. Health Care Women Int (2002) 0.86
Trans-10, cis-12 conjugated linoleic acid increases fatty acid oxidation in 3T3-L1 preadipocytes. J Nutr (2002) 0.85
Accumulation of p53 protein is frequent in ovarian cancers associated with BRCA1 and BRCA2 germline mutations. J Clin Pathol (1999) 0.85
Differences between hereditary and sporadic ovarian cancer. Eur J Obstet Gynecol Reprod Biol (1999) 0.84
Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Br J Cancer (2009) 0.84
Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Fam Cancer (2010) 0.84
Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. J Proteomics (2015) 0.83
Relationship between underlying renal disease and renal transplantation outcome. Am J Kidney Dis (2001) 0.83
Polyphenol-rich grape powder extract (GPE) attenuates inflammation in human macrophages and in human adipocytes exposed to macrophage-conditioned media. Int J Obes (Lond) (2010) 0.83
Comparative genomic hybridization of microdissected familial ovarian carcinoma: two deleted regions on chromosome 15q not previously identified in sporadic ovarian carcinoma. Lab Invest (2001) 0.83
Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women. Cancer (1999) 0.83
Handling missing data in nursing research with multiple imputation. Nurs Res (2001) 0.82